JP2015504519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504519A5 JP2015504519A5 JP2014543882A JP2014543882A JP2015504519A5 JP 2015504519 A5 JP2015504519 A5 JP 2015504519A5 JP 2014543882 A JP2014543882 A JP 2014543882A JP 2014543882 A JP2014543882 A JP 2014543882A JP 2015504519 A5 JP2015504519 A5 JP 2015504519A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- tia
- sample
- amount
- developed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010019280 Heart failures Diseases 0.000 claims description 29
- 230000002490 cerebral effect Effects 0.000 claims description 20
- 230000000302 ischemic effect Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 210000004351 coronary vessel Anatomy 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 13
- 208000006011 Stroke Diseases 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 4
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 24
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 23
- 230000001052 transient effect Effects 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 description 12
- 102400001263 NT-proBNP Human genes 0.000 description 7
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 7
- 206010007556 Cardiac failure acute Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 208000008253 Systolic Heart Failure Diseases 0.000 description 4
- 208000037849 arterial hypertension Diseases 0.000 description 4
- 208000018578 heart valve disease Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11191579 | 2011-12-01 | ||
| EP11191579.9 | 2011-12-01 | ||
| PCT/EP2012/073897 WO2013079567A2 (en) | 2011-12-01 | 2012-11-29 | Nt-proanp and nt-probnp for the diagnosis of stroke |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016239317A Division JP6441885B2 (ja) | 2011-12-01 | 2016-12-09 | 脳卒中診断のためのＮＴ−ｐｒｏＡＮＰ及びＮＴ−ｐｒｏＢＮＰ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504519A JP2015504519A (ja) | 2015-02-12 |
| JP2015504519A5 true JP2015504519A5 (https=) | 2016-10-20 |
| JP6059735B2 JP6059735B2 (ja) | 2017-01-11 |
Family
ID=47278813
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543882A Active JP6059735B2 (ja) | 2011-12-01 | 2012-11-29 | 脳卒中診断のためのＮＴ−ｐｒｏＡＮＰ及びＮＴ−ｐｒｏＢＮＰ |
| JP2016239317A Active JP6441885B2 (ja) | 2011-12-01 | 2016-12-09 | 脳卒中診断のためのＮＴ−ｐｒｏＡＮＰ及びＮＴ−ｐｒｏＢＮＰ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016239317A Active JP6441885B2 (ja) | 2011-12-01 | 2016-12-09 | 脳卒中診断のためのＮＴ−ｐｒｏＡＮＰ及びＮＴ−ｐｒｏＢＮＰ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10732188B2 (https=) |
| EP (2) | EP3290924B1 (https=) |
| JP (2) | JP6059735B2 (https=) |
| CN (2) | CN107064516B (https=) |
| CA (2) | CA3081979C (https=) |
| ES (2) | ES2899923T3 (https=) |
| WO (1) | WO2013079567A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3206032B1 (en) * | 2014-10-10 | 2019-02-27 | Akira Matsumori | Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure |
| KR20210038893A (ko) * | 2018-07-31 | 2021-04-08 | 에프. 호프만-라 로슈 아게 | 심방 세동의 평가에서 순환하는 dkk3(딕오프 관련 단백질 3) |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US20220381794A1 (en) * | 2019-05-16 | 2022-12-01 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Method for selecting a patient for a reperfusion therapy |
| JP2021173559A (ja) | 2020-04-21 | 2021-11-01 | 株式会社デンソー | 物理量計測装置 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| EP1322957B1 (en) | 2001-05-04 | 2009-08-12 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| DE60233949D1 (de) | 2001-08-20 | 2009-11-19 | Biosite Inc | Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon |
| ATE462001T1 (de) * | 2002-12-24 | 2010-04-15 | Nitto Boseki Co Ltd | Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit |
| JP2006526140A (ja) * | 2002-12-24 | 2006-11-16 | バイオサイト インコーポレイテッド | 鑑別診断のためのマーカーおよびその使用方法 |
| US20050181386A1 (en) * | 2003-09-23 | 2005-08-18 | Cornelius Diamond | Diagnostic markers of cardiovascular illness and methods of use thereof |
| EP1582597A1 (en) | 2004-03-29 | 2005-10-05 | Aventis Pharma Deutschland GmbH | Method of diagnosis of a predisposition to develop thrombotic disease and its uses |
| US20060166303A1 (en) * | 2005-01-24 | 2006-07-27 | Eberhard Spanuth | Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs |
| DK1849009T3 (da) | 2005-01-24 | 2009-01-12 | Hoffann La Roche Ag F | Anvendelse af cardiachormoner til diagnose af cardiovaskulære risici som fölge af en administration af antiinflammatoriske lægemidler |
| JP4828550B2 (ja) * | 2005-02-17 | 2011-11-30 | エフ．ホフマン−ラ ロシュ アーゲー | 心機能障害を診断するためのＮＴ−ｐｒｏＡＮＰ／ＮＴ−ｐｒｏＢＮＰ比の使用 |
| EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| DE102005048899A1 (de) * | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Diagnose thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| ES2344993T3 (es) * | 2006-03-24 | 2010-09-13 | F. Hoffmann-La Roche Ag | Medios y metodos para la diferenciacion de la necrosis de miocardio aguda y cronica en pacientes sintomaticos. |
| EP1882945A1 (en) | 2006-07-28 | 2008-01-30 | F.Hoffmann-La Roche Ag | Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath |
| ATE449966T1 (de) * | 2006-09-15 | 2009-12-15 | Hoffmann La Roche | Biochemische marker für akute lungenembolie |
| JP2011501113A (ja) | 2007-10-10 | 2011-01-06 | エフ．ホフマン−ラ ロシュ アーゲー | 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド／トロポニン比 |
| CN102257386B (zh) * | 2008-10-24 | 2014-12-31 | B.R.A.H.M.S有限公司 | 通过测定标志肽的水平在已患过中风或短暂性缺血性发作的患者中进行预后和风险评估 |
| CA2751090A1 (en) * | 2009-01-30 | 2010-08-05 | Electrophoretics Limited | Method for the in vitro diagnosis of stroke |
| EP2466311A1 (en) | 2010-12-17 | 2012-06-20 | Roche Diagnostics GmbH | sFlt1 in patients with ischemic stroke |
-
2012
- 2012-11-29 EP EP17196637.7A patent/EP3290924B1/en active Active
- 2012-11-29 CN CN201610812599.8A patent/CN107064516B/zh active Active
- 2012-11-29 JP JP2014543882A patent/JP6059735B2/ja active Active
- 2012-11-29 CA CA3081979A patent/CA3081979C/en active Active
- 2012-11-29 ES ES17196637T patent/ES2899923T3/es active Active
- 2012-11-29 CN CN201280068882.4A patent/CN104094121B/zh active Active
- 2012-11-29 ES ES12794941.0T patent/ES2656082T3/es active Active
- 2012-11-29 WO PCT/EP2012/073897 patent/WO2013079567A2/en not_active Ceased
- 2012-11-29 CA CA2856461A patent/CA2856461C/en active Active
- 2012-11-29 EP EP12794941.0A patent/EP2786154B1/en active Active
-
2014
- 2014-05-30 US US14/291,676 patent/US10732188B2/en active Active
-
2016
- 2016-12-09 JP JP2016239317A patent/JP6441885B2/ja active Active
-
2020
- 2020-06-30 US US16/916,809 patent/US20200333360A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504519A5 (https=) | ||
| Kardys et al. | C-reactive protein and risk of heart failure. The Rotterdam Study | |
| Moura et al. | Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology | |
| JP2025013795A (ja) | 消化管手術を受けた患者のｍａｃｃｅの診断方法 | |
| Pfister et al. | Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? | |
| JP2015531873A5 (https=) | ||
| Agewall et al. | Myocardial infarction with angiographically normal coronary arteries | |
| Kagawa et al. | Comparison of heart-type fatty acid binding protein and sensitive troponin for the diagnosis of early acute myocardial infarction | |
| Ross et al. | Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review | |
| Fairley et al. | Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis | |
| CN111710425A (zh) | 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置 | |
| Simpson et al. | Echocardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic evaluation | |
| Laufs et al. | Cardiological evaluation after cerebral ischaemia: Consensus statement of the Working Group Heart and Brain of the German Cardiac Society—Cardiovascular Research (DGK) and the German Stroke Society (DSG) | |
| Rezk et al. | Highly-sensitive C-reactive protein level and its association with intermediate and high syntax score in cases of acute coronary syndrome | |
| JP6316200B2 (ja) | サイクロフィリンａによる心血管疾患の検査方法 | |
| Chien et al. | Stratifying the optimal thresholds of point-of-care testing NT-proBNP as acute heart failure marker in elder patients with impaired kidney function | |
| RU2806237C1 (ru) | Способ прогнозирования развития ремоделирования левого желудочка после инфаркта миокарда с подъемом сегмента ST и сердечной недостаточности с использованием многофакторной регрессионной модели | |
| JP7584125B2 (ja) | 心血管イベントの発症リスクの検査方法 | |
| Morawiec et al. | COPeptin for diagnosis and prediction in Acute Coronary Syndrome (COPACS) Study: design and objectives | |
| Shahi et al. | Association of ankle brachial pressure index (ABPI) in patients with ischemic stroke: A case control study | |
| JP2020051911A (ja) | 心不全マーカー | |
| Cwikiel et al. | P826 Increase in cardiac biomarkers during exercise stress test in patients with angiographically verified coronary artery disease | |
| Ljung et al. | P827 Insufficient sensitivity when using undetectable baseline high-sensitivity cardiac troponin T (hs-cTnT< 5 ng/L) to rule out myocardial infarction in patients with short time from symptom onset | |
| Tan et al. | Does Sex-Specific High-Sensitivity Troponin T Cut-Off Values Alter Clinical Outcomes in Chest Pain Presentations to the Emergency Department? | |
| Mashahit et al. | High Sensitivity C-Reactive Protein Level In Sera Of Pre-Diabetic And Newly Diagnosed Type 2 Diabetic Patients |